How Does THC Actually Make You High? The Cellular Mechanism Explained

Most explanations of how marijuana makes a person high stop at "THC affects the brain." For employers trying to understand workplace impairment risk — and for anyone who wants to know what's actually happening biologically — that explanation is not enough. The real answer sits in what happens inside the cells: how THC physically reaches the brain, what specific protein it binds to, and what cascade of changes occurs inside individual nerve cells that produces everything from memory disruption to euphoria to slowed reaction time.

This article walks through the cellular mechanism in five steps, drawing on peer-reviewed neuroscience research from the National Institutes of Health, Nature, and Neuroscience. A companion article in this series covers the different types of marijuana and what science says about strain effects.

Step 1: How THC enters the bloodstream

The route of consumption fundamentally changes how fast THC enters the body and how strong the effect is.

Inhaled cannabis (smoking, vaporizing)

When cannabis is inhaled, THC enters the bloodstream through the lungs. Peer-reviewed pharmacokinetic research published in PMC documents that:

• Peak blood levels occur within 6 to 10 minutes of inhalation
• Bioavailability is roughly 10% to 35% — meaning that fraction of the THC actually reaches systemic circulation
• The remainder is lost to combustion, exhalation, and incomplete absorption

Inhalation produces the fastest onset and the highest peak blood concentrations of THC, which is why the high arrives quickly and feels intense.

Ingested cannabis (edibles, oils, tinctures)

When cannabis is consumed orally, THC takes a different and slower route. It is absorbed through the digestive tract and travels through the liver before reaching the bloodstream — a process called first-pass metabolism.

First-pass metabolism is significant because the liver converts a substantial portion of delta-9 THC into a different molecule: 11-hydroxy-THC. According to clinical research, 11-hydroxy-THC is itself psychoactive — and often produces stronger and longer-lasting effects than the parent THC molecule. This is why edibles are notorious for unexpectedly strong highs.

The pharmacokinetics of oral cannabis:

• Onset is slow — 30 minutes to 2 hours
• Peak effects can occur 2 to 4 hours after ingestion
• Total impairment window can extend to 6 to 8 hours or more, particularly with higher doses

This delayed onset is one reason novice users often consume more than they intended — they don't feel the first dose, take a second, and end up substantially over-dosed by the time the first dose peaks.

Step 2: Crossing the blood-brain barrier

This is the step most non-scientific explanations skip, and it's where the actual chemistry of why THC produces a high becomes clear. THC cannot affect the brain without first reaching the brain — and reaching the brain requires crossing the blood-brain barrier (BBB).

What the blood-brain barrier is

The blood-brain barrier is a highly selective protective layer of cells that separates the brain from the rest of the body's circulation. According to peer-reviewed research published in PMC, the BBB is formed by tightly joined endothelial cells lining the brain's blood vessels, supported by surrounding glial cells. Its job is to prevent most substances in the bloodstream from reaching brain tissue — protecting the brain from toxins, pathogens, and large molecules that could disrupt neural function.

Why THC crosses easily

The blood-brain barrier blocks most substances. THC crosses it rapidly because of one specific chemical property: lipophilicity. THC is fat-soluble, not water-soluble. The blood-brain barrier is itself a lipid (fat-based) membrane, so fat-soluble molecules pass through it readily, while water-soluble molecules largely cannot.

This is why THC produces psychoactive effects within minutes of inhalation. The same chemical property that lets THC reach the brain quickly is what causes it to linger in fatty tissue throughout the body for days or weeks — the long detection-window problem in workplace drug testing. THC's lipophilicity is responsible for both the rapid onset of effects AND the persistent presence of cannabinoids in the body long after the high has ended.

THC also affects the barrier itself

Recent peer-reviewed research has documented that THC does not just pass through the blood-brain barrier — it interacts with cannabinoid receptors on the endothelial cells that form the barrier. A 2025 study published in Neuroscience found that THC exposure can cause measurable changes to blood-brain barrier integrity through CB1 receptor activation and oxidative stress mechanisms. This is an active area of ongoing research and is one reason chronic cannabis use is being studied for potential effects on cerebrovascular health.

Step 3: Binding to the CB1 receptor

Once inside the brain, THC encounters the receptor it was structurally designed (in evolutionary terms, by the cannabis plant's chemistry) to fit into.

What CB1 receptors are

According to NIH-cited neuroscience research, the CB1 receptor is a G protein-coupled receptor (GPCR) — a specific class of protein embedded in the membranes of cells. CB1 receptors are concentrated on presynaptic neurons — the nerve cells that send signals to other nerve cells — particularly in regions of the brain involved in:

• Cognition and decision-making (orbitofrontal cortex)
• Memory formation (hippocampus)
• Motor control (cerebellum, basal ganglia)
• Reward processing (mesolimbic system)

CB1 receptors normally respond to the body's own internal cannabinoids — anandamide and 2-AG — which act as neurotransmitters in the endocannabinoid system, fine-tuning communication between nerve cells.

How THC fits the receptor

THC's molecular structure is similar enough to anandamide and 2-AG that THC binds to and activates CB1 receptors. According to peer-reviewed pharmacology research, THC is a partial agonist at CB1 — meaning it activates the receptor, but not as fully as the body's own natural cannabinoids do. THC's binding is also longer-lasting than the body's natural cannabinoids, which are produced and broken down quickly. This combination — strong binding affinity plus delayed breakdown — is why THC can dominate the system once it arrives.

When a person consumes cannabis, THC overwhelms the endocannabinoid system, attaching to cannabinoid receptors throughout the brain and body in concentrations far higher than natural endocannabinoid signaling produces. This is the moment where the high actually begins.

Step 4: What happens inside the nerve cell

This is where the high originates at the cellular level. When THC binds to a CB1 receptor on the membrane of a nerve cell, the receptor undergoes a conformational change — a shift in its physical shape — that triggers a cascade of changes inside the cell.

According to peer-reviewed neuroscience research, the cascade follows these steps:

1. The receptor activates an intracellular G-protein — specifically the inhibitory Gi/o type of G-protein
2. The G-protein suppresses adenylyl cyclase, an enzyme that produces a key cellular messenger molecule called cyclic AMP (cAMP)
3. Voltage-gated calcium channels close — preventing calcium from entering the cell
4. Potassium channels open — letting potassium flow out of the cell
5. The combined effect hyperpolarizes the presynaptic terminal — making the nerve cell electrochemically less likely to fire and release neurotransmitters

The net result of this cascade: THC binding to CB1 receptors makes affected nerve cells less likely to release the neurotransmitters they normally use to communicate with other nerve cells. This is sometimes called retrograde signaling — the CB1 receptor sits on the cell that sends signals, and activating it reduces the cell's signaling output.

This sounds simple but is profoundly disruptive in practice, because the brain regions where CB1 receptors are most concentrated are the regions that govern memory, attention, motor coordination, judgment, and reward — exactly the functions that matter for safe workplace performance.

Step 5: Why the high feels the way it does

The subjective experience of being high — altered perception, changes in mood, impaired memory and coordination, time distortion, euphoria — is the downstream consequence of nerve cells failing to communicate normally in specific brain regions:

• Disrupted communication in the hippocampus → impaired short-term memory formation. This is why people don't remember conversations or events from while they were high.
• Disrupted communication in the orbitofrontal cortex → impaired attention, decision-making, and ability to shift focus between tasks.
• Disrupted communication in the cerebellum and basal ganglia → impaired balance, coordination, and reaction time.
• Activation of dopamine release in the brain's reward system → euphoria and the sense of pleasure that contributes to marijuana's addictive properties.

The reason the effects feel like they happen "all at once" is that THC reaches CB1 receptors throughout the brain at roughly the same time, and the disruption to nerve cell communication is happening simultaneously in all these regions. This is also why even a moderate dose impairs multiple distinct cognitive and motor functions at the same time — it's not affecting one system; it's reducing communication efficiency across an entire signaling network.

What this means for workplace impairment

Understanding the cellular mechanism explains a few practical realities that often come up in workplace drug screening conversations:

• Why a worker can be impaired without "looking" obviously high. The disruption happens at the cellular level in specific brain regions. Some workers compensate visibly better than others, but the underlying impairment to memory, reaction time, and judgment is happening regardless of outward appearance.
• Why edibles produce stronger and longer-lasting impairment. First-pass metabolism converts more of the THC into 11-hydroxy-THC, which is itself psychoactive and has a longer duration in the body than inhaled delta-9 THC alone.
• Why workers can be impaired the morning after evening use. The impairment window can extend 6 to 8 hours or more for moderate-to-high doses, and chronic users who have built up THC stores in fatty tissue can experience residual effects beyond the typical acute window.
• Why "I only used a low-THC product" is not a reliable defense against impairment. The same THC molecule binds to the same CB1 receptors regardless of the package label. Dose and recency matter; product framing does not change the receptor pharmacology.
• Why oral fluid testing aligns better with impairment than urine testing. Oral fluid primarily detects active delta-9 THC — the molecule actually causing the effects described above. Urine testing primarily detects inactive metabolites that are produced after the impairing molecule has been broken down.

Final takeaway

THC produces a high through a five-step cellular process: (1) absorption through the lungs or digestive system, (2) crossing the blood-brain barrier rapidly because of its fat-solubility, (3) binding to CB1 receptors on presynaptic nerve cells throughout the brain, (4) triggering a G-protein cascade that suppresses cyclic AMP, closes calcium channels, and opens potassium channels — making the nerve cell less likely to fire — and (5) producing the subjective experience of being high as the downstream consequence of disrupted communication between nerve cells in brain regions controlling memory, attention, motor coordination, and reward. The mechanism is the same regardless of cannabis strain or category. For employer drug screening programs, understanding this mechanism explains why cannabis impairment is real and measurable at the cellular level — and why testing methods that target active THC (the molecule actually causing these effects) align better with impairment than methods that target inactive metabolites.

Sourcing rapid tests for your workplace screening program?

At My BIO TESTS®, we supply rapid, CLIA-Waived FDA 510(k)–cleared drug screening tests, plus Employer & Insurance Use Only and Forensic Use Only options for employer programs. We focus on helping safety-sensitive and multi-location organizations standardize fast, reliable onsite screening workflows with trusted product supply.

Choosing between urine and oral fluid testing for your THC program?

→ Compare rapid urine and oral fluid drug screens for employers

Or call 737-333-5566 | email info@mybiotests.com

Sources

• National Institutes of Health / PMC, "Cannabinoids, Blood–Brain Barrier, and Brain Disposition"
• National Institutes of Health / PMC, "Mechanisms of Action and Pharmacokinetics of Cannabis"
• National Institutes of Health / PMC, "Molecular Mechanism and Cannabinoid Pharmacology"
• National Institutes of Health / PMC, "Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function"
• Neuroscience (ScienceDirect), "Δ9-tetrahydrocannabinol induces blood-brain barrier disruption: Involving the activation of CB1R and oxidative stress" (2025)
• American Medical Association, "All about cannabis pharmacology" (2024)
• National Institute on Drug Abuse, "Cannabis (Marijuana) — How does marijuana produce its effects?"

---

Disclosure: My BIO TESTS® sells rapid urine and oral fluid drug screening tests in three regulatory categories: CLIA-Waived FDA 510(k)–cleared, Employer & Insurance Use Only, and Forensic Use Only. Selection of the appropriate category depends on your testing program and use case. Positive results from any rapid screening test are presumptive and should be confirmed by an HHS-certified laboratory and reviewed by a qualified Medical Review Officer (MRO). This content is educational and is not medical, legal, or scientific advice for any specific testing program. Consult qualified professional counsel before making policy or testing decisions for your workforce.

Last updated: May 2026